Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07118202 · ClinicalTrials.gov registry record · NA
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
A NA study of Hepatocellular Carcinoma Recurrent, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 198
- Enrollment target
- 6
- Study locations
NCT07118202 is a NA study of Hepatocellular Carcinoma Recurrent that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 198 participants. The trial reports 6 study locations across 1 state.
The verdict
NCT07118202, a NA study of Hepatocellular Carcinoma Recurrent, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 198 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect overall survival in advance HCC * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
Conditions Studied
Interventions
- DEVICE TheraBionic P1
Study Locations (6)
Michigan
- Karmanos Cancer Institute at McLaren Bay Region - Bay City
- Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute at McLaren Flint - Flint
- Karmanos Cancer Institute at McLaren Greater Lansing - Lansing
- Karmanos Cancer Institute at McLaren Lapeer Region - Lapeer
- Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center - Mount Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07118202
The ClinicalTrials.gov registry entry for NCT07118202 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma Recurrent appearing as the primary indexed condition, and to 1 intervention - of which TheraBionic P1 is the first listed.
NCT07118202 reports 6 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07118202 about?
NCT07118202 is a clinical study titled "TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma". The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect overall surviv...
What is the current status of trial NCT07118202?
This trial is currently recruiting. It is a NA study. The enrollment target is 198 participants. The study started on 2025-10-20. Estimated completion is 2027-08-31.
What conditions does trial NCT07118202 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma Recurrent.
What interventions are being tested in trial NCT07118202?
The interventions under investigation include: TheraBionic P1 (DEVICE).
Who is sponsoring clinical trial NCT07118202?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07118202 being conducted?
This trial has 6 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.